ArticleJACC. Case reports2026
Dilated Cardiomyopathy in a Woman With SPG4-Associated Hereditary Spastic Paraplegia.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- SPG4-Associated Hereditary Spastic Paraplegia and Dilated Cardiomyopathy: Coincidence or Clue?JACC. Case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHereditary spastic paraplegia (HSP) is primarily an inherited neurodegenerative disorder, although reports suggest possible systemic involvement. Cardiac manifestations in SPG4-HSP remain poorly understood, and dilated cardiomyopathy (DCM) has not previously been documented. CASE SUMMARY: A 54-year-old woman with genetically confirmed SPG4-HSP presented with progressive dyspnea and a new left bundle branch block. Echocardiography and cardiac magnetic resonance revealed nonischemic DCM with reduced ejection fraction and dyssynchrony. Alternative causes were excluded, and extended cardiomyopathy gene testing was negative. Guideline-directed medical therapy was initiated with symptomatic improvement at outpatient follow up, and she subsequently received cardiac resynchronization therapy with defibrillator given persistent low ejection fraction and dyssynchrony. DISCUSSION/NOVELTY: To the best of our knowledge, this is the first reported experience of coexisting SPG4-HSP and idiopathic DCM. While causality remains uncertain, the case highlights a potential cardiac phenotype in SPG4 and underscores the importance of targeted cardiac evaluation in HSP patients presenting with exertional symptoms. TAKE-HOME MESSAGES: Cardiac symptoms in SPG4-HSP warrant structured cardiac assessment. Standard heart-failure therapy and device management remain applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.